Cargando…

Doxycycline-Induced Expression of Transgenic Human Tumor Necrosis Factor α in Adult Mice Results in Psoriasis-like Arthritis

OBJECTIVE: To generate doxycycline-inducible human tumor necrosis factor α (TNFα)–transgenic mice to overcome a major disadvantage of existing transgenic mice with constitutive expression of TNFα, which is the limitation in crossing them with various knockout or transgenic mice. METHODS: A transgeni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Retser, Eugen, Schied, Tanja, Skryabin, Boris V, Vogl, Thomas, Kanczler, Janos M, Hamann, Nina, Niehoff, Anja, Hermann, Sven, Eisenblätter, Michel, Wachsmuth, Lydia, Pap, Thomas, van Lent, Peter L E M, Loser, Karin, Roth, Johannes, Zaucke, Frank, Ludwig, Stephan, Wixler, Viktor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2013
Materias:	Experimental Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798087/ https://www.ncbi.nlm.nih.gov/pubmed/23740547 http://dx.doi.org/10.1002/art.38026

Ejemplares similares

The LIM-Only Protein FHL2 Attenuates Lung Inflammation during Bleomycin-Induced Fibrosis
por: Alnajar, Abdulaleem, et al.
Publicado: (2013)

Inflammatory Cytokines Stabilize SOXC Transcription Factors to Mediate the Transformation of Fibroblast‐Like Synoviocytes in Arthritic Disease
por: Bhattaram, Pallavi, et al.
Publicado: (2018)

Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis
por: Tweehuysen, Lieke, et al.
Publicado: (2018)

Deletion of activin A in mesenchymal but not myeloid cells ameliorates disease severity in experimental arthritis
por: Waltereit-Kracke, Vanessa, et al.
Publicado: (2022)

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study
por: Feist, Eugen, et al.
Publicado: (2022)

Economic and Comorbidity Burden Among Moderate‐to‐Severe Psoriasis Patients with Comorbid Psoriatic Arthritis
por: Feldman, Steven R., et al.
Publicado: (2015)

Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities
por: Koehm, Michaela, et al.
Publicado: (2023)

Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trials
por: Champs, Bénédicte, et al.
Publicado: (2019)

Characterization and Function of Tumor Necrosis Factor and Interleukin‐6–Induced Osteoclasts in Rheumatoid Arthritis
por: Yokota, Kazuhiro, et al.
Publicado: (2021)

Psoriasis and the risk of foot and ankle tendinopathy or enthesopathy in the absence of psoriatic arthritis: a population-based study
por: Lewinson, Ryan T, et al.
Publicado: (2018)

Tissue‐Resident Memory CD8+ T Cells From Skin Differentiate Psoriatic Arthritis From Psoriasis
por: Leijten, Emmerik F., et al.
Publicado: (2021)

Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study
por: Colaco, Keith, et al.
Publicado: (2022)

Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling
por: Soomro, Mehreen, et al.
Publicado: (2022)

Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study
por: Tillett, William, et al.
Publicado: (2023)

Tolerability of low to moderate biomechanical stress during leisure sport activity in patients with psoriasis and psoriatic arthritis
por: Fagni, Filippo, et al.
Publicado: (2023)

Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis
por: Low, Audrey S. L., et al.
Publicado: (2016)

Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register
por: Soliman, Moetaza M, et al.
Publicado: (2012)

Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease
por: Mellor, Liliana F, et al.
Publicado: (2022)

Metabolic Profiling Predicts Response to Anti–Tumor Necrosis Factor α Therapy in Patients With Rheumatoid Arthritis
por: Kapoor, Sabrina R, et al.
Publicado: (2013)

Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti–tumor necrosis factor therapies
por: Saad, Amr A, et al.
Publicado: (2010)

Replication of Association of the PTPRC Gene With Response to Anti–Tumor Necrosis Factor Therapy in a Large UK Cohort
por: Plant, Darren, et al.
Publicado: (2012)

Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis
por: Nurmohamed, Michael, et al.
Publicado: (2015)

Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis
por: Huynh, D H, et al.
Publicado: (2017)

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors
por: Weitz, Jeffrey I, et al.
Publicado: (2022)

Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease‐Modifying Antirheumatic Drug Treatment
por: Sparks, Jeffrey A., et al.
Publicado: (2019)

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure
por: Mease, P, et al.
Publicado: (2015)

Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis
por: Sauer, Brian C., et al.
Publicado: (2017)

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors
por: Strand, Vibeke, et al.
Publicado: (2017)

Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients’ offspring
por: Smeele, Hieronymus T W, et al.
Publicado: (2022)

Attenuation of Rheumatoid Arthritis Through the Inhibition of Tumor Necrosis Factor–Induced Caspase 3/Gasdermin E–Mediated Pyroptosis
por: Zhai, Zeqing, et al.
Publicado: (2022)

Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA
por: Regierer, Anne Constanze, et al.
Publicado: (2023)

Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study
por: Kim, Seoyoung C., et al.
Publicado: (2017)

Selective Inhibition of Membrane Type 1 Matrix Metalloproteinase Abrogates Progression of Experimental Inflammatory Arthritis: Synergy With Tumor Necrosis Factor Blockade
por: Kaneko, Kazuyo, et al.
Publicado: (2016)

Treatment of Rheumatoid Arthritis With Anti–Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study
por: Choy, Ernest H., et al.
Publicado: (2017)

Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
por: Fleischmann, Roy, et al.
Publicado: (2017)

Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis
por: Virone, Alexandre, et al.
Publicado: (2019)

Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland
por: Finckh, A, et al.
Publicado: (2020)

Phase II/III Results of a Trial of Anti–Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2022)

Response to abatacept is associated with the inhibition of proteasome β1i expression in T cells of patients with rheumatoid arthritis
por: Ghannam, Khetam, et al.
Publicado: (2020)

Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results
por: Smolen, Josef S, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t5iso7d391vnhnku9kd28egvvr